pipette
ESEspañol

Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis

Jonathan Barratt, Robert M. Brenner, Sean J. Barbour, Kirk Nicholas Campbell, Tom Doan, Necmi Eren, Jürgen Floege, Marshall W. Fordyce, Vivekanand Jha, Zeeshan Khawaja, Beom Seok Kim, Adrian Liew, Bart Maes, Atanu Pal, Roberto Pecoits‐Filho, Richard K. S. Phoon, Dana V. Rizk, Hitoshi Suzuki, Vladimı́r Tesař, Hernán Trimarchi, Xuelian Wei, Lixi Yu, Hong Zhang, Richard A. Lafayette

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
ConclusionsAtacicept slowed and stabilized the decline in the eGFR as compared with placebo.

Appeared: Saturday, October 24. New England Journal of Medicine. Peer-reviewed journal.

DOI: 10.1056/nejmoa2610103